The Skin Cancer Foundation
March 1, 2020
Merkel cell carcinoma (MCC) is not a common skin cancer, but it is a very dangerous one. The number of cases has increased dramatically in the past decade. Luckily, knowledge and treatment options have surged, too. Paul Nghiem, MD, PhD, director of the Skin Oncology Clinical Program at the Seattle Cancer Care Alliance and head of Dermatology at the University of Washington School of Medicine, among other titles, has worked tirelessly to promote research and collaboration to create better outcomes for MCC patients who previously had little hope.
With so many advances on the horizon, we thought this was a good time to raise awareness among dermatologists and other medical professionals about MCC in our current issue of Carcinomas & Keratoses. With his well-known energy and enthusiasm, Dr. Nghiem engaged in a lively conversation with Julie Bain, The Skin Cancer Foundation’s senior director of science & education, and Désirée Ratner, MD, our C&K editor-in-chief, to share his expertise and shed light on the most important advancements in his field.
The authoritative source on Merkel cell carcinoma.
September 22, 2020
- What is a Merkel cell?
- What is Merkel cell carcinoma?
- Symptoms & appearance of Merkel cell carcinoma
- Causes of Merkel cell carcinoma
- Surgical excision
- Mohs micrographic surgery
- Radiation therapy
- Complementary & alternative therapies
- Clinical trials
- Adjuvant Avelumab in Merkel Cell Carcinoma Trial